John Parker | Managing Partner
Springhood Ventures

John Parker, Managing Partner, Springhood Ventures

John Parker is the Founder and Managing Partner of Springhood Ventures, an early-stage venture capital firm that invests in life science and healthcare companies transforming the health and care of children. Mr. Parker founded Springhood following his success creating and managing CH Innovations, the impact-first venture capital subsidiary of the Charles H. Hood Foundation, a Boston-based family foundation that supports pediatric research, where he also serves as a trustee. John is currently a director or observer on the boards of Kamal Therapeutics, Plakous Therapeutics, Deck Therapeutics, SmolTap, Argus Cognitive, Anida Pharma, and Prapela, Inc.. He also serves on the advisory boards of multiple nonprofit entities, largely around mission-driven healthcare investing, including serving on the advisory boards of Harvard's Wyss Institute and MIT Health and Life Sciences Collaborative. He is a frequent speaker on pediatric innovation and mission investing. Previously, John spent 25 years in the alternative investment industry, including senior roles in venture capital, private equity, and hedge funds. Early in his career he worked in international merchant banking. Although currently living in the Boston area, John spent portions of his career in New York, Tokyo, and Sydney and has done business in over 20 countries on 6 continents. John has a BA from Dartmouth College and an MBA from Dartmouth’s Tuck School of Business.    

Appearances:



Day 2 - World Orphan Drug Congress USA 2026 @ 14:30

Doing Well Through Doing Good: Investing in Rare Disease Drugs

Orphan disease drug development and commercialization is often fragmented - with an inefficient clinical development model, an incorrect way of measuring Return of Investment and a commercial model that is often unattractive vis-a-vis other disease states. Imagine an approach where there is access to knowledge, infrastructure and mission-dedicated evergreen capital to systematically develop new medicines for orphan diseases. Imagine an investment vehicle with dual objectives: Return on mission- curing rare diseases and Return on capital: Making money while doing that! In this panel, we will discuss both the operational and capitalization novelties in this new model. Capital allocations from foundations and family offices / UHNWIs can enable such a construct, along with an infrastructure support system from hospitals, scientists, drug manufacturers. 

last published: 13/May/26 12:45 GMT

back to speakers

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 

 

To Sponsor Or Exhibit

 
 

Jack Rendell
jack.rendell@terrapinn.com
t/ +44 07577689029

 

 

 

To Speak

 
 

Abdu Kauroo
abdu.kauroo@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Jasper Cameron
jasper.cameron@terrapinn.com